Dicot Pharma towards listing on Nasdaq First North
Uppsala, Sweden, September 23, 2024. The pharmaceutical company Dicot Pharma AB engages FNCA Sweden AB as Certified advisor as part of the preparations for a listing on Nasdaq First North Growth Market. The listing is expected to take place in November 2024, at the same time as delisting from Spotlight Stock Market.The Board of Directors of Dicot Pharma believes that a listing on Nasdaq First North will benefit Dicot's continued development, internationalization and competitiveness. The listing applies to both Dicot Pharma's share and warrant of series TO6. All companies listed on First